CSE | OTC | FSE

novamentis life science

The Nova Mission

We’re a Canadian-based biotechnology company and global leader in psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders. Our mission is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder and fragile X syndrome.

 

Our Holdings

novamentis biotech

Nova Mentis Biotech

Wholly owned subsidiary investigating medicinal psychedelics. Current focus indications: obesity, diabetes, liver disease (NASH)

Learn More


Pilz BioScience

Pilz Bioscience

Wholly owned subsidiary investigating medicinal psychedelics. Current focus indications: Autism Spectrum Disorder

Learn More

Nova Mentis Life Science
Stock Performance

CSE FSE

Latest News

Nova Mentis Organizes Autism Data Bank in North America

Vancouver, British Columbia – April 20, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that it will be organizing a North American autism spectrum disorder (ASD) data bank to support the company’s development of psilocybin-based compounds in...

Nova Mentis Establishes Serotonin Research Centre

Vancouver, British Columbia – March 31, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that it is establishing a serotonin research centre in partnership with FourthWall Testing, in Winter Garden, Florida.

NOVA’s neuroinflammatory research program is based on ...